IN2014DN10652A - - Google Patents
Info
- Publication number
- IN2014DN10652A IN2014DN10652A IN10652DEN2014A IN2014DN10652A IN 2014DN10652 A IN2014DN10652 A IN 2014DN10652A IN 10652DEN2014 A IN10652DEN2014 A IN 10652DEN2014A IN 2014DN10652 A IN2014DN10652 A IN 2014DN10652A
- Authority
- IN
- India
- Prior art keywords
- pyrrolobenzodiazepine
- methods
- same
- covalently attached
- cd79b antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The invention provides immunoconjugates comprising anti CD79b antibodies covalently attached to a pyrrolobenzodiazepine and methods of using the same.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261669270P | 2012-07-09 | 2012-07-09 | |
PCT/US2013/049517 WO2014011519A1 (en) | 2012-07-09 | 2013-07-08 | Immunoconjugates comprising anti-cd79b antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN10652A true IN2014DN10652A (en) | 2015-09-11 |
Family
ID=48803622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN10652DEN2014 IN2014DN10652A (en) | 2012-07-09 | 2013-07-08 |
Country Status (24)
Country | Link |
---|---|
US (2) | US20140030280A1 (en) |
EP (1) | EP2869850B1 (en) |
JP (1) | JP2015523380A (en) |
KR (1) | KR20150030753A (en) |
CN (1) | CN104540526A (en) |
AR (1) | AR091700A1 (en) |
AU (1) | AU2013288930A1 (en) |
BR (1) | BR112015000437A2 (en) |
CA (1) | CA2873884A1 (en) |
CL (1) | CL2015000029A1 (en) |
CO (1) | CO7151530A2 (en) |
CR (1) | CR20150049A (en) |
EA (1) | EA201590171A1 (en) |
ES (1) | ES2643225T3 (en) |
HK (1) | HK1209042A1 (en) |
IL (1) | IL235807A0 (en) |
IN (1) | IN2014DN10652A (en) |
MA (1) | MA37840B1 (en) |
MX (1) | MX2015000359A (en) |
PE (1) | PE20150211A1 (en) |
PH (1) | PH12014502827A1 (en) |
SG (1) | SG11201500093TA (en) |
TW (1) | TW201408698A (en) |
WO (1) | WO2014011519A1 (en) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101802013B (en) | 2007-07-16 | 2014-07-02 | 健泰科生物技术公司 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
NZ583367A (en) | 2007-07-16 | 2012-10-26 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
MX2010008437A (en) | 2008-01-31 | 2010-11-25 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use. |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
AU2011239522B2 (en) | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
MX368648B (en) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases. |
WO2013041606A1 (en) | 2011-09-20 | 2013-03-28 | Spirogen Sàrl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
JP6393617B2 (en) | 2011-10-14 | 2018-09-19 | シアトル ジェネティクス,インコーポレーテッド | Pyrrolobenzodiazepine and target conjugates |
EA027386B1 (en) | 2011-10-14 | 2017-07-31 | Медимьюн Лимитед | Pyrrolobenzodiazepines |
JP6399930B2 (en) | 2011-10-14 | 2018-10-03 | シアトル ジェネティクス,インコーポレーテッド | Pyrrolobenzodiazepine and target conjugates |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
AU2013328628B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
DK2906296T3 (en) | 2012-10-12 | 2018-05-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
ES2680153T3 (en) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Anti-PSMA-pyrrolobenzodiazepine antibody conjugates |
RS58921B1 (en) | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
SI2906253T1 (en) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
PT3470086T (en) | 2012-10-12 | 2021-02-01 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP2935273A1 (en) | 2012-12-21 | 2015-10-28 | MedImmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
KR102066318B1 (en) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | Pyrrolobenzodiazepines and conjugates thereof |
EA027910B1 (en) | 2013-03-13 | 2017-09-29 | Медимьюн Лимитед | Pyrrolobenzodiazepines and conjugates thereof |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
DK3160513T3 (en) | 2014-06-30 | 2020-04-06 | Glykos Finland Oy | SACCHARIDE DERIVATIVES OF A TOXIC PAYLOAD AND ANTIBODY CONJUGATES THEREOF |
GB201412658D0 (en) * | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
KR20170055521A (en) * | 2014-09-17 | 2017-05-19 | 제넨테크, 인크. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
LT3262071T (en) | 2014-09-23 | 2020-06-25 | F. Hoffmann-La Roche Ag | Method of using anti-cd79b immunoconjugates |
KR101657962B1 (en) * | 2014-10-16 | 2016-09-21 | 렉스젠(주) | Apparatus for inputting vehicle number and method thereof |
BR112017011111A2 (en) | 2014-11-25 | 2017-12-26 | Adc Therapeutics Sa | pyrrolobenzodiazepine-antibody conjugates |
US9975949B2 (en) | 2014-12-05 | 2018-05-22 | Genentech, Inc. | Anti-CD79b antibodies and methods of use |
DE102015106405A1 (en) * | 2015-04-27 | 2016-10-27 | Intel IP Corporation | METHOD AND DEVICES BASED ON DYNAMIC RECEPTION DIVERSITY |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
WO2017049139A2 (en) * | 2015-09-17 | 2017-03-23 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US10143695B2 (en) | 2016-05-18 | 2018-12-04 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
CN109641910A (en) | 2016-06-24 | 2019-04-16 | 梅尔莎纳医疗公司 | Pyrroles acene phenodiazine * and its conjugate |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
JP2020517609A (en) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | Pyrrolobenzodiazepine complex |
MX2019015042A (en) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc. |
CN111065638B (en) | 2017-08-18 | 2021-04-09 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepine conjugates |
CA3177158A1 (en) | 2017-09-29 | 2019-04-04 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
CN111757757A (en) | 2017-12-21 | 2020-10-09 | 梅尔莎纳医疗公司 | Pyrrolobenzodiazepine antibody conjugates |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CN111116745B (en) * | 2018-11-01 | 2022-10-14 | 上海新理念生物医药科技有限公司 | anti-CD79b antibody, drug conjugate thereof and application thereof |
CN113286821A (en) | 2018-12-21 | 2021-08-20 | 豪夫迈·罗氏有限公司 | Tumor-targeting agonistic CD28 antigen binding molecules |
CN113286823A (en) | 2019-01-28 | 2021-08-20 | 上海拓界生物医药科技有限公司 | anti-CD 79B antibody, antigen binding fragment thereof and medical application thereof |
TW202100556A (en) | 2019-03-14 | 2021-01-01 | 美商建南德克公司 | Treatment with her2 t cell-dependent bispecific antibodies |
EP4094779A4 (en) * | 2020-01-22 | 2023-11-22 | Shanghai Senhui Medicine Co., Ltd. | Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine |
WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
WO2022098628A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
IL302217A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
CN114891123B (en) * | 2022-06-09 | 2024-02-09 | 北京美康基免生物科技有限公司 | Chimeric antigen receptor based on CD79b humanized antibody and application thereof |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ATE503496T1 (en) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS |
ES2091684T3 (en) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | THERAPEUTIC APPLICATION OF CHEMICAL AND RADIO-MARKED ANTIBODIES AGAINST THE RESTRICTED DIFFERENTIATION ANTIGEN OF HUMAN B-LYMPHOCYTES FOR THE TREATMENT OF B-CELL LYMPHOMA. |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (en) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
PT1068241E (en) | 1998-04-02 | 2007-11-19 | Genentech Inc | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1071700T3 (en) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity |
DE69925133T2 (en) | 1998-08-27 | 2006-01-19 | Spirogen Ltd., Ryde | PYRROLOBENZODIAZEPINE |
EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
ES2248127T3 (en) | 1999-10-04 | 2006-03-16 | Medicago Inc. | METHOD FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NIGTROGEN. |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | Process for producing polypeptide |
IL149809A0 (en) | 1999-12-15 | 2002-11-10 | Genentech Inc | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
LT2857516T (en) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalent antibodies and uses therefor |
BR0114475A (en) | 2000-10-06 | 2003-12-23 | Kyowa Hakko Kogyo Kk | Cell for the production of antibody composition |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
JP2005532253A (en) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | Glycoprotein composition |
US20050123536A1 (en) | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
AU2003236015A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
EP1500698B1 (en) | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
EP1498485A4 (en) | 2002-04-09 | 2006-09-06 | Kyowa Hakko Kogyo Kk | Cells with modified genome |
JPWO2003084569A1 (en) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | Antibody composition-containing medicine |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP4351674B2 (en) | 2002-12-16 | 2009-10-28 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants and their use and use |
EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
DE60326060D1 (en) | 2003-03-31 | 2009-03-19 | Council Scient Ind Res | Non-Crosslinking PYRROLOA2,1-CÜ1,4ÜBENZODIAZEPINE AS POTENTIAL ANTITUMOR AGENTS AND THEIR PREPARATION |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
JPWO2005035778A1 (en) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | Method for producing antibody composition using RNA that suppresses function of α1,6-fucosyltransferase |
US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
BR122018071808B8 (en) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugate |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
WO2005085260A1 (en) | 2004-03-09 | 2005-09-15 | Spirogen Limited | Pyrrolobenzodiazepines |
AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2067789A1 (en) | 2004-04-13 | 2009-06-10 | F. Hoffmann-La Roche Ag | Anti-P selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
RU2412947C2 (en) | 2004-09-23 | 2011-02-27 | Дженентек, Инк. | Antibodies, constructed on cysteine basis and their conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
ES2577292T3 (en) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Binding polypeptides with diversified VH / VL hypervariable sequences and consensus |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
ATE527262T1 (en) | 2006-01-25 | 2011-10-15 | Sanofi Sa | NEW CYTOTOXIC AGENTS CONTAINING TOMAYMYCIN DERIVATIVES |
WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
CA2652945C (en) | 2006-05-30 | 2015-06-02 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
CN101622276B (en) | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | Antagonist antibody against EphA2 for the treatment of cancer |
EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
NZ583367A (en) | 2007-07-16 | 2012-10-26 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
PL2019104T3 (en) | 2007-07-19 | 2014-03-31 | Sanofi Sa | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
MX2010008437A (en) * | 2008-01-31 | 2010-11-25 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use. |
TWI540136B (en) | 2010-04-15 | 2016-07-01 | 梅迪繆思有限公司 | Pyrrolobenzodiazepines and conjugates thereof |
-
2013
- 2013-07-08 IN IN10652DEN2014 patent/IN2014DN10652A/en unknown
- 2013-07-08 TW TW102124410A patent/TW201408698A/en unknown
- 2013-07-08 BR BR112015000437A patent/BR112015000437A2/en active Search and Examination
- 2013-07-08 CA CA2873884A patent/CA2873884A1/en not_active Abandoned
- 2013-07-08 WO PCT/US2013/049517 patent/WO2014011519A1/en active Application Filing
- 2013-07-08 US US13/936,280 patent/US20140030280A1/en not_active Abandoned
- 2013-07-08 KR KR20157003033A patent/KR20150030753A/en not_active Application Discontinuation
- 2013-07-08 MA MA37840A patent/MA37840B1/en unknown
- 2013-07-08 EP EP13739332.8A patent/EP2869850B1/en active Active
- 2013-07-08 CN CN201380036617.2A patent/CN104540526A/en active Pending
- 2013-07-08 EA EA201590171A patent/EA201590171A1/en unknown
- 2013-07-08 JP JP2015521675A patent/JP2015523380A/en active Pending
- 2013-07-08 ES ES13739332.8T patent/ES2643225T3/en active Active
- 2013-07-08 AU AU2013288930A patent/AU2013288930A1/en not_active Abandoned
- 2013-07-08 SG SG11201500093TA patent/SG11201500093TA/en unknown
- 2013-07-08 MX MX2015000359A patent/MX2015000359A/en unknown
- 2013-07-08 AR ARP130102422 patent/AR091700A1/en unknown
- 2013-07-08 PE PE2015000010A patent/PE20150211A1/en not_active Application Discontinuation
-
2014
- 2014-11-20 IL IL235807A patent/IL235807A0/en unknown
- 2014-11-28 CO CO14262535A patent/CO7151530A2/en unknown
- 2014-12-18 PH PH12014502827A patent/PH12014502827A1/en unknown
-
2015
- 2015-01-07 CL CL2015000029A patent/CL2015000029A1/en unknown
- 2015-02-04 CR CR20150049A patent/CR20150049A/en unknown
- 2015-10-06 HK HK15109751.3A patent/HK1209042A1/en unknown
-
2017
- 2017-06-21 US US15/628,813 patent/US20180169259A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180169259A1 (en) | 2018-06-21 |
CR20150049A (en) | 2015-03-13 |
KR20150030753A (en) | 2015-03-20 |
TW201408698A (en) | 2014-03-01 |
CL2015000029A1 (en) | 2015-02-27 |
EA201590171A1 (en) | 2015-09-30 |
SG11201500093TA (en) | 2015-02-27 |
JP2015523380A (en) | 2015-08-13 |
WO2014011519A1 (en) | 2014-01-16 |
CN104540526A (en) | 2015-04-22 |
BR112015000437A2 (en) | 2017-06-27 |
ES2643225T3 (en) | 2017-11-21 |
AU2013288930A1 (en) | 2014-12-04 |
CO7151530A2 (en) | 2014-12-29 |
AR091700A1 (en) | 2015-02-25 |
HK1209042A1 (en) | 2016-03-24 |
US20140030280A1 (en) | 2014-01-30 |
MX2015000359A (en) | 2015-04-14 |
MA37840B1 (en) | 2020-05-29 |
EP2869850A1 (en) | 2015-05-13 |
IL235807A0 (en) | 2015-01-29 |
CA2873884A1 (en) | 2014-01-16 |
PH12014502827A1 (en) | 2015-02-02 |
MA37840A3 (en) | 2018-11-30 |
EP2869850B1 (en) | 2017-08-23 |
PE20150211A1 (en) | 2015-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN10652A (en) | ||
PH12014502797A1 (en) | Immunoconjugates comprising anti-cd22 antibodies | |
PH12014502826A1 (en) | Immunoconjugates comprising anti-cd79b antibodies | |
PH12014502825A1 (en) | Immunoconjugates comprising anti-cd22 antibodies | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
PH12018500046A1 (en) | Anti-mesothelin antibodies and immunoconjugates | |
PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
PH12015501954A1 (en) | Anti-b7-h4 antibodies and immunoconjugates | |
HK1207987A1 (en) | Anti-pmel17 antibodies and immunoconjugates pmel17 | |
IL238567A0 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
MY176285A (en) | Anti-fcrh5 antibodies | |
MX2013011479A (en) | Anti-fgfr4 antibodies and methods of use. | |
EP2879708A4 (en) | Anti-etbr antibodies and immunoconjugates | |
MX2014004022A (en) | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE. | |
PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
MX2014002053A (en) | Anti-mcsp antibodies. | |
MX2014014376A (en) | Anti-biotin antibodies and methods of use. | |
MX2012011829A (en) | Anti-polyubiquitin antibodies and methods of use. | |
MX353951B (en) | Anti-theophylline antibodies and methods of use. | |
EP2879711A4 (en) | Anti-etbr antibodies and immunoconjugates |